Axsome Therapeutics, Inc.(AXSM)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Axsome Therapeutics, Inc. (AXSM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AXSM at 40.8/100 on a 32-signal composite quality model, placing it at rank #2,087 of 2,961 stocks — the bottom half of the AI-ranked universe. AXSM scores in the top quartile across revenue growth (95.4). Areas of concern include balance sheet strength (8.6) and profitability (16.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Axsome Therapeutics, Inc. reports quarterly revenue of $218.4M, net income of $-51.3M, an operating margin of -22.7%. Top institutional holders of AXSM by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. AXSM trades on the Nasdaq exchange and files with the SEC under CIK 1579428. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AXSM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Axsome Therapeutics, Inc. directly from SEC EDGAR.